Stifel Financial Corp Theratechnologies Inc. Transaction History

Stifel Financial Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.78 - $1.01 $1,560 - $2,020	2,000 Added 0.56%	358,236 $300,000
Q1 2023 May 12, 2023	SELL	$0.72 - $1.12 $1,013 - $1,575	-1,407 Reduced 0.39%	356,236 $288,000
Q4 2022 Feb 13, 2023	BUY	$0.83 - $2.3 $1,167 - $3,236	1,407 Added 0.39%	357,643 $314,000
Q2 2022 Aug 15, 2022	SELL	$2.21 - $2.7 $24,575 - $30,024	-11,120 Reduced 3.03%	356,236 $809,000
Q1 2022 May 13, 2022	BUY	$2.37 - $3.24 $5,389 - $7,367	2,274 Added 0.62%	367,356 $900,000

Q4 2021 Feb 14, 2022	BUY	$2.92 - $3.76 $226,127 - $291,178	77,441 Added 26.92%	365,082 $1.11 Million
Q3 2021 Nov 15, 2021	BUY	$3.28 - $4.07 $103,008 - $127,818	31,405 Added 12.26%	287,641 $1.08 Million
Q2 2021 Aug 13, 2021	BUY	$3.43 - $3.96 $61,225 - $70,686	17,850 Added 7.49%	256,236 $994,000
Q4 2020 Feb 12, 2021	SELL	$1.91 - $2.5 $4,775 - $6,250	-2,500 Reduced 1.04%	238,386 $596,000
Q3 2020 Nov 16, 2020	SELL	$1.96 - $2.92 $507 - $756	-259 Reduced 0.11%	240,886 $532,000
Q1 2020 May 14, 2020	BUY	$1.43 - $3.23 $370 - $836	259 Added 0.11%	241,145 $387,000
Q4 2019 Feb 13, 2020	BUY	$2.74 - $4.2 $660,027 - $1.01 Million	240,886 New	240,886 $797,000

29.2K

Ticker THTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,141,600
Market Cap $135M
Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with l...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.